Purulent-inflammatory complications developing after cesarean section remain one of the leading causes of maternal morbidity and complications in obstetric practice. Despite the widespread use of antibiotic therapy, the increasing prevalence of antibiotic-resistant microorganisms and biofilm formation significantly limits treatment effectiveness. This literature review analyzes scientific studies published over the past five years and highlights the potential of a comprehensive approach based on phage therapy in the treatment of post-cesarean purulent-inflammatory complications. The high specificity of bacteriophages, their ability to disrupt biofilms, and their synergistic effect with antibiotics make them a promising therapeutic option for the management of postoperative infections.

Cesarean section, purulent-inflammatory complications, postoperative infection

Wang B., Zheng P., Zhang Y., et al. Current knowledge and perspectives of phage therapy for combating refractory wound infections // International Journal of Molecular Sciences. – 2024. – Vol. 25, № 10. – P. 5465.

Łusiak-Szelachowska M., Międzybrodzki R., Weber-Dąbrowska B., et al. Bacteriophages in the treatment of infections caused by antibiotic-resistant bacteria // Antibiotics. – 2020. – Vol. 9, № 9. – P. 567.

Abedon S.T., García P., Mullany P., Aminov R. Phage therapy: past, present and future // Frontiers in Microbiology. – 2019. – Vol. 10. – P. 2754.

Pirnay J.P., De Vos D., Verbeken G., et al. The phage therapy paradigm: prêt-à-porter or sur-mesure? // Pharmaceutical Research. – 2020. – Vol. 37, № 4. – P. 1–17.

Gordillo Altamirano F., Barr J.J. Phage therapy in the postantibiotic era // Clinical Microbiology Reviews. – 2019. – Vol. 32, № 2. – e00066-18.

Kortright K.E., Chan B.K., Koff J.L., Turner P.E. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria // Cell Host & Microbe. – 2019. – Vol. 25, № 2. – P. 219–232.

Lin D.M., Koskella B., Lin H.C. Phage therapy: An alternative to antibiotics in the age of multidrug resistance // World Journal of Gastrointestinal Pharmacology and Therapeutics. – 2020. – Vol. 11, № 1. – P. 1–10.

Verbeken G., Pirnay J.P., Lavigne R., et al. Call for a dedicated European legal framework for bacteriophage therapy // Archives of Immunology and Therapy Experimental. – 2020. – Vol. 68, № 3. – P. 1–10.

Aslam S., Pretorius V., Lehman S.M., et al. Novel bacteriophage therapy for treatment of resistant bacterial infections // Clinical Infectious Diseases. – 2020. – Vol. 71, № 7. – P. 1857–1865.

Zhvania P., Hoyle N.S., Nadareishvili L., et al. Phage therapy in postoperative wound infections: clinical experience // Journal of Wound Care. – 2021. – Vol. 30, № 2. – P. 102–110.

Dedrick R.M., Guerrero-Bustamante C.A., Garlena R.A., et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant infection // Nature Medicine. – 2019. – Vol. 25, № 5. – P. 730–733.

Rohde C., Wittmann J., Kutter E. Bacteriophages: A therapy concept against multidrug-resistant bacteria // Surgical Infections. – 2021. – Vol. 22, № 3. – P. 1–8.